


REVIVING HOPE



With a **median OS of 23 months**, RYBREVANT® (Amivantamab) offers a **second chance** for NSCLC patients with **EGFR Ex20ins+** whose disease has progressed on or after platinum-based chemotherapy¹

EGFR Ex20ins+

RYBREVANT® (Amivantamab) is the **first and only** **therapy** approved for **EGFR Ex20ins+** whose disease has progressed on or after platinum-based chemotherapy².



NCCN Guidelines® recommend RYBREVANT® (Amivantamab) as a subsequent therapy option for patients that have progressed on or after platinum-based chemotherapy and have **EGFR exon 20 insertion mutation-positive NSCLC (Category 2A recommendation)**.³

Abbreviations: EGFR: epidermal-growth factor receptor; Ex20ins+: Exon 20 Insertion Mutations; NSCLC: non-small cell lung cancer; OS: overall survival; NCCN: National Comprehensive Cancer Network

References: 1. Garrido P, et al. Oral presented at ELCC 2023; abstract 779.; 2. Singapore RYBREVANT® Package Insert - Approved 28 Apr2023; 3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer V.1.2024. To view the most recent and complete version of the guideline, go online to [NCCN.org](https://www.nccn.org). Accessed December 2023.

 **RYBREVANT®**
(amivantamab)